With the advent of stable-isotopically labeled multiple reaction monitoring (MRM) in proteomics, there is an increased need for peptide reagents for proteomics research. The Clinical Proteomics Technology Assessment for Cancer is generating hundreds of peptides for planned interlaboratory experiments. Remaining reagents will be available via this portal at a future date.